The Manila Times59m
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of ...
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...
Clinical Trials Arena on MSN2d
Incyte stock hit 11% despite paediatric dermatology trials hitting target
The US company’s two simultaneous trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.
GlobalData on MSN5mon
Priovant mulls broad autoimmune indications for brepocitinib
Whilst most of the autoimmune space is dominated by monoclonal antibodies like AbbVie’s Humira (adalimumab), GlobalData ...
BioWorld3d
Street less than JAK’d about Incyte phase III data in HS
Investors wanted more from Incyte Corp.’s top-line results in hidradenitis suppurativa (HS) from its pivotal phase III Stop-HS trial program with oral small-molecule JAK1 inhibitor povorcitinib in ...
MedPage Today on MSN6d
Rapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 Inhibitor
ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...